Do you want to read an article? Please log in or register.
Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial
Heart Failure
Related content
Heart FailureFurther Publications
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic Substudy
J Am Heart Assoc
Patel-Murray NL, Zhang L, Claggett BL, Xu D, Serrano-Fernandez P, Healey M, Wandel S, Chen CW, Jacob J, Xu H, Turner GM, Chutkow W, Yates DP, O'Donnell CJ, Prescott MF, Lefkowitz M, Gimpelewicz CR, Beste MT, Zhao F, Gou L, Desai AS, Jhund PS, Packer M, Pfeffer MA, Redfield MM, Rouleau JL, Zannad F, Zile MR, McMurray JJV, Mendelson MM, Solomon SD, Cunningham JW
doi: 10.1161/JAHA.123.033544
Heart Failure
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial
Eur J Heart Fail
Solomon SD, Ostrominski JW, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Ma CS, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesová E, Kang SM, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperón G, Mareev V, Martinez FA, Melenovský V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov LG, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Viswanathan P, McMurray JJV
doi: 10.1002/ejhf.3266
Heart Failure
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HF
Eur J Heart Fail
Wang X, Vardeny O, Claggett B, Vaduganathan M, Hegde SM, Skali H, Pabon MA, Foà A, Chatur S, Kosztin A, O'Meara E, Rouleau J, Redfield M, Lam CSP, Zile M, Packer M, Shah AM, Cikes M, Gori M, Merkely B, Pfeffer MA, McMurray JJV, Solomon SD
doi: 10.1002/ejhf.3535
Heart Failure
Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
JAMA Cardiol
Cunningham JW, Chatur S, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Llamas Esperón G, Lam CSP, Sato N, Senni M, Shah S, Voors A, Zannad F, Pitt B, Zieroth S, Brinker M, Rohwedder K, Kim SY, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD
doi: 10.1001/jamacardio.2025.0016
Heart Failure
Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial
JAMA Cardiol
Desai AS, Jhund PS, Vaduganathan M, Claggett BL, Cunningham JW, Pabon MA, Lam CSP, Senni M, Shah S, Voors AA, Zannad F, Pitt B, Amarante F, Lay-Flurrie J, Scheerer MF, Lage A, McMurray JJV, Solomon SD
doi: 10.1001/jamacardio.2025.0860
Heart Failure
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial
Eur J Heart Fail
Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lam CSP, Mueller K, Scheerer MF, Viswanathan P, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV
doi: 10.1002/ejhf.3661
COMMENTED
Heart Failure
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Lancet Diabetes Endocrinol
Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN, STEP-HFpEF Trials Committees and Investigators
doi: 10.1016/S2213-8587(24)00304-8
Heart Failure
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
JAMA Cardiol
Chimura M, Wang X, Jhund PS, Henderson AD, Claggett BL, Desai AS, Fonseca C, Goncalvesova E, Katova T, Mueller K, Glasauer A, Rohwedder K, Viswanathan P, Nodari S, Lam CSP, Saldarriaga CI, Senni M, Sharma K, Voors AA, Zannad F, Pitt B, Vardeny O, Vaduganathan M, Solomon SD, McMurray JJV
doi: 10.1001/jamacardio.2024.4613
Heart Failure
In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial
J Am Heart Assoc
Nouhravesh N, Cyr D, Hernandez AF, Morrow DA, Velazquez EJ, Ward J, Sarwat S, Sharma K, Williamson K, Starling RC, Lepage S, Zieroth S, Solomon SD, Mentz RJ
doi: 10.1161/JAHA.124.037899